Imatinib mesylate provides good results in the treatment of CML in general. But what about the results of this treatment in CML\r\nassociated with additional cytogenetic abnormalities at diagnosis among black Africans? For this, we retrospectively studied 27\r\ncases of CML associated with additional cytogenetic abnormalities, diagnosed in the department of clinical hematology of the\r\nUniversity Hospital of Yopougon in CÃ?â? ote dââ?¬â?¢Ivoire, from May 2005 to October 2011. The age of patients ranged from 13 to 68 years,\r\nwith amean age of 38 years and a sex ratio of 2. Patients were severely symptomatic with a high Sokal score of 67%. CML in chronic\r\nphase accounted for 67%.Theprevalence of additional cytogenetic abnormalities was 29.7%. Therewere variants of the Philadelphia\r\nchromosome (18.5%), trisomy 8 (14.8%), complex cytogenetic abnormalities (18.5%), second Philadelphia chromosome (14.8%), and\r\nminor cytogenetic abnormalities (44.4%). Complete hematologic remission was achieved in 59%, with 52% of major cytogenetic\r\nremission. The outcome was fatal in 37% of patients. Death was related in 40% to hematologic toxicity and in 30% to acutisation.\r\nThe median survival was 40 months.
Loading....